CD4 and influenza: Because of these contributions to persistent protective immunity to viruses and the necessity of enhancing broader and more robust antibody responses to vaccination, the studies reported here focused on the potential of the novel adjuvant R-DOTAP, when combined with a licensed influenza recombinant protein vaccine, to elicit multifunctional CD4+ T cells specific for peptides contained in recombinant HA-based protein vaccines.